The Role of Neuromodulation Technique In Depression Disorder

NCT ID: NCT05047159

Last Updated: 2022-10-27

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 450 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-11-01
• Study Completion Date: 2024-06-30

Brief Summary

This study aims to explore the efficacy, safety and long-term effects of common and available non-invasive neuromodulation techniques in the treatment of depression, and to provide a data basis for the establishment of individualized treatment and efficacy prediction models. 450 patients will be enrolled and randomly assigned to five different treatments. Psychopathological assessment will be performed in both acute and maintenance phases of treatment with the Hamilton Depression Rating Scale, the Hamilton Anxiety Rating Scale, and the Patient Health Questionaire-9, the Sheehan Disability Scale, the Vascular Quality of Life-6 Questionnaire respectively.

Conditions

Depressive Disorder, Major

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

drug therapy group

Drug: drug therapy There is no restriction on the choice of therapeutic drugs.

Group Type: EXPERIMENTAL

drug therapy

Intervention Type: DRUG

There is no restriction on the choice of therapeutic drugs.

drug therapy combined with repetitive transcranial magnetic stimulation (rTMS) group

Device: rTMS Stimulation will be performed for 20 working days once a day (4 weeks). Extend course to 30 sessions (6 weeks) in responders who have not achieved symptom remission.

Frequency: 10Hz; Intensity: 110% RMT; Coil-type: F8; Sessions-pulse: 3000; Site: the left dorsolateral prefrontal cortex.

Drug: drug therapy There is no restriction on the choice of therapeutic drugs.

Group Type: EXPERIMENTAL

rTMS

Intervention Type: DEVICE

Stimulation will be performed for 20 working days once a day (4 weeks). Extend course to 30 sessions (6 weeks) in responders who have not achieved symptom remission.

Frequency: 10Hz; Intensity: 110% RMT; Coil-type: F8; Sessions-pulse: 3000; Site: the left dorsolateral prefrontal cortex.

drug therapy

Intervention Type: DRUG

There is no restriction on the choice of therapeutic drugs.

drug therapy combined with light therapy group

Device: light therapy Active 10,000-lux fluorescent white light box for 30 min/d in the early morning for 6 weeks.

Drug: drug therapy There is no restriction on the choice of therapeutic drugs.

Group Type: EXPERIMENTAL

light therapy

Intervention Type: DEVICE

Active 10,000-lux fluorescent white light box for 30 min/d in the early morning for 6 weeks.

drug therapy

Intervention Type: DRUG

There is no restriction on the choice of therapeutic drugs.

drug therapy combined with electroconvulsive therapy (ECT) group

Device: ECT The electrode placements are bifrontal (BF); the electrical intensity is 1.5 to 2.0 times the seizure threshold (ST); 3 times per week.

Drug: drug therapy There is no restriction on the choice of therapeutic drugs.

Group Type: EXPERIMENTAL

ECT

Intervention Type: DEVICE

The electrode placements are bifrontal (BF); the electrical intensity is 1.5 to 2.0 times the seizure threshold (ST); 3 times per week.

drug therapy

Intervention Type: DRUG

There is no restriction on the choice of therapeutic drugs.

drug therapy combined with magnetic seizure therapy (MST) group

Device: MST A coil placement at the vertex (i.e., Cz in 10-20 electroencephalogram [EEG] system) with a frequency of stimulation of 100 Hz, pulse width of 0.2 to 0.4 ms, and stimulation duration of 10 seconds; 2 times per week.

Drug: drug therapy There is no restriction on the choice of therapeutic drugs.

Group Type: EXPERIMENTAL

MST

Intervention Type: DEVICE

A coil placement at the vertex (i.e., Cz in 10-20 electroencephalogram \[EEG\] system) with a frequency of stimulation of 100 Hz, pulse width of 0.2 to 0.4 ms, and stimulation duration of 10 seconds; 2 times per week.

drug therapy

Intervention Type: DRUG

There is no restriction on the choice of therapeutic drugs.

Interventions

rTMS

Stimulation will be performed for 20 working days once a day (4 weeks). Extend course to 30 sessions (6 weeks) in responders who have not achieved symptom remission.

Frequency: 10Hz; Intensity: 110% RMT; Coil-type: F8; Sessions-pulse: 3000; Site: the left dorsolateral prefrontal cortex.

Intervention Type: DEVICE

light therapy

Active 10,000-lux fluorescent white light box for 30 min/d in the early morning for 6 weeks.

Intervention Type: DEVICE

ECT

The electrode placements are bifrontal (BF); the electrical intensity is 1.5 to 2.0 times the seizure threshold (ST); 3 times per week.

Intervention Type: DEVICE

MST

A coil placement at the vertex (i.e., Cz in 10-20 electroencephalogram \[EEG\] system) with a frequency of stimulation of 100 Hz, pulse width of 0.2 to 0.4 ms, and stimulation duration of 10 seconds; 2 times per week.

Intervention Type: DEVICE

drug therapy

There is no restriction on the choice of therapeutic drugs.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Age 18-60;

2. Meet the DSM-IV "major Depressive Episode" diagnostic criteria and are currently in the depressive episode (MDE) stage;

3. The 17-item Hamilton Depression Scale (HAMD-17) score was > 17, and the HAMD-17 item 1 (depression) score was ≥2;

4. Failure to respond adequately to at least one of the new antidepressants (including a HAMD-17 reduction rate of less than 50% and an intolerant drug side effect);

5. Junior high school education or above, with sufficient audio-visual understanding of the research content, and signed the informed consent;

6. If drug therapy is used at the same time, the medication regimen should remain unchanged at least 4 weeks before the follow-up group, and continue to remain unchanged during the neurological intervention in the acute phase;

7. Right-handed.

Exclusion Criteria

1. Schizophrenia, or psychotic symptoms unrelated to depression, bipolar disorder, eating disorder, etc.;Personality disorders and mental retardation;Patients with depression caused by physical diseases;

2. Suffering from the following serious diseases:History of brain injury or cerebrovascular accident, narrow-angle glaucoma, epilepsy, myocardial infarction, unstable angina pectoris, congestive heart failure, severe cirrhosis, acute and chronic renal failure, severe diabetes, aplastic anemia,Moderate to severe malnutrition and other serious neurological, heart, liver, kidney, endocrine, blood system and other physical diseases or diseases that may interfere with the study (abnormal index is more than 2 times the normal value);

3. Patients with metal implants or electronic instruments (such as embedded intracranial electrodes, cochlea, medical pump, etc.), photosensitive dermatitis and other skin diseases or other contraindications in the body;

4. Intracranial mass, cerebral infarction, increased intracranial pressure, or other active central nervous system disease, including epilepsy;Dementia, delirium, memory loss or other cognitive disorders;Brain trauma that increases the risk of seizures;

5. Severe drug allergic reaction;

6. Pregnant, lactating or planning to become pregnant;

7. Substance abuse (excluding caffeine and nicotine) in the past 3 months;

8. Received rTMS, tDCS, tACS, light therapy, ECT, MST, DBS therapy in the past 3 months;

9. Serious suicide attempt (hamD-17 item 3 "suicide" score ≥3);

10. Refuse to sign the informed consent.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Shanghai Mental Health Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Shanghai Mental Health Center

Shanghai, Shanghai Municipality, China

Countries

China

Other Identifiers

2020-74

Identifier Type: -

Identifier Source: org_study_id